Table 5.
Sensitivity analyses of high-heterogeneity outcomes.
| Heterogeneity outcome | Excluded trials | Group TXA (n) | Group placebo (n) | Heterogeneity |
Analysis model | WMD | 95% CI | Overall effect P | |
|---|---|---|---|---|---|---|---|---|---|
| I 2 | P | ||||||||
| Post-op 6 h IL-6 | (20, 25) | 190 | 189 | 70% | <0.0001 | IV, Fixed | −11.84 | (−14.78, −8.91) | 0.005 |
| Post-op 24 h IL-6 | (22) | 240 | 239 | 98% | <0.00001 | IV, Fixed | −3.95 | (−4.80, −3.11) | <0.00001 |
| Post-op 24 h IL-8 | (24) | 28 | 29 | 90% | 0.002 | IV, Fixed | −12.82 | (−19.15, −6.49) | <0.0001 |
| Post-op 24 h TNF-α | (22) | 198 | 159 | 66% | 0.01 | IV, Fixed | −0.56 | (−1.21, 0.09) | 0.09 |
| Post-op 6 h NE | (16) | 120 | 120 | 0% | 0.85 | IV, Fixed | −90.01 | (−116.57, −63.45) | <0.00001 |
| Post-op 24 h NE | (16) | 120 | 120 | 0% | 0.65 | IV, Fixed | −198.38 | (−220.34, −176.42) | <0.00001 |
Post-op, postoperative; WMD, weighted mean difference. 95% CI, 95% confidence interval; IL, interleukin; TNF-α, tumor necrosis factor-alpha; NE, neutrophil elastase.